Medulloblastoma Associated with Down Syndrome: From a Rare Event Leading to a Pathogenic Hypothesis
Authors:
- Alessandra BoniABAlessandra Boni
- Marco RanalliMRMarco Ranalli
- Giada Del BaldoGBGiada Del Baldo
- Roberto CartaRCRoberto Carta
- Mariachiara LodiMLMariachiara Lodi
- Emanuele AgoliniEAEmanuele Agolini
- Martina RinelliMRMartina Rinelli
- Diletta ValentiniDVDiletta Valentini
- Sabrina RossiSRSabrina Rossi
- Viola AlesiVAViola Alesi
- Antonella CacchioneACAntonella Cacchione
- Evelina MieleEvelina Miele
Open Access
- 7 February 2021
- journal article
- case report
- Published by MDPI AG in Diagnostics
- Vol. 11 (2) , 254
Abstract
Down syndrome (DS) is the most common chromosome abnormality with a unique cancer predisposition syndrome pattern: a higher risk to develop acute leukemia and a lower incidence of solid tumors. In particular, brain tumors are rarely reported in the DS population, and biological behavior and natural history are not well described and identified. We report a case of a 10-year-old child with DS who presented with a medulloblastoma (MB). Histological examination revealed a classic MB with focal anaplasia and the molecular profile showed the presence of a CTNNB1 variant associated with the wingless (WNT) molecular subgroup with a good prognosis in contrast to our case report that has shown an early metastatic relapse. The nearly seven-fold decreased risk of MB in children with DS suggests the presence of protective biological mechanisms. The cerebellum hypoplasia and the reduced volume of cerebellar granule neuron progenitor cells seem to be a possible favorable condition to prevent MB development via inhibition of neuroectodermal differentiation. Moreover, the NOTCH/WNT dysregulation in DS, which is probably associated with an increased risk of leukemia, suggests a pivotal role of this pathway alteration in the pathogenesis of MB; therefore, this condition should be further investigated in future studies by molecular characterizations.Keywords
This publication has 44 references indexed in Scilit:
- Molecular subgroups of medulloblastoma: the current consensusActa Neuropathologica, 2011
- Hematological disorders and leukemia in children with Down syndromeEuropean Journal of Pediatrics, 2011
- Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroupsActa Neuropathologica, 2011
- TP53 Mutation Is Frequently Associated With CTNNB1 Mutation or MYCN Amplification and Is Compatible With Long-Term Survival in MedulloblastomaJournal of Clinical Oncology, 2010
- Subtypes of medulloblastoma have distinct developmental originsNature, 2010
- Medulloblastoma in a child with down syndrome: Long-term remission with multimodality treatmentPediatric Blood & Cancer, 2009
- A systems biology approach to Down syndrome: Identification of Notch/Wnt dysregulation in a model of stem cells agingBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2009
- Malignancy in Children with Trisomy 21The Oncologist, 2009
- A Medical Enigma: Persons with Down Syndrome Do Not Develop MedulloblastomaNeuroepidemiology, 2008
- Wnt/Wingless Pathway Activation and Chromosome 6 Loss Characterise a Distinct Molecular Sub-Group of Medulloblastomas Associated with a Favourable PrognosisCell Cycle, 2006